



# DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update

May 07, 2024, 16:30 ET

CUPERTINO, Calif., May 7, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: [DRRX](#)), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its first quarter financial results on Monday, May 13, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows:

## ***Monday, May 13th @ 4:30 pm Eastern Time / 1:30 pm Pacific Time***

**Toll Free:** 1-877-407-0784 or 1-201-689-8560

**Conference ID:** 13746111

**Call Me:** <https://callme.viavid.com/viavid/?callme=true&passcode=13740526&h=true&info=company-email&r=true&B=6>

Participants can use guest dial-in numbers above to reach an operator or they can click the Call me<sup>TM</sup> link for instant telephone access to the event (dial-out). The Call me<sup>TM</sup> link will be made active 15 minutes prior to the scheduled start time.

**Webcast:** [https://viavid.webcasts.com/starthere.jsp?ei=1666995&tp\\_key=b63f08cf47](https://viavid.webcasts.com/starthere.jsp?ei=1666995&tp_key=b63f08cf47)

## **About DURECT Corporation**

DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the U.S. Food and Drug Administration (FDA) has granted a Fast Track Designation. In addition, POSIMIR<sup>®</sup> (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER<sup>®</sup> platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States. For more information about DURECT, please visit [www.durect.com](http://www.durect.com) and follow us on X (formerly Twitter) at <https://x.com/DURECTCorp>.

## **DURECT Forward-Looking Statements**

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: our plans to report first quarter financial results on May 13, 2024 and the potential for larsucosterol to demonstrate a reduction in mortality or liver transplant in patients with AH and to save lives. Actual results may differ materially from those contained in the forward-looking statements contained in this press release, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from those projected include, among other things, the risk that future clinical trials of larsucosterol are delayed or do not confirm the results from subset analyses of the AHFIRM trial, including geographic or other segmentation, or of earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy of larsucosterol in a statistically significant manner; the risk that the FDA or other government agencies may require additional clinical trials for larsucosterol before approving larsucosterol for the treatment of AH, and that larsucosterol may never be approved; risks that Innocoll may not commercialize POSIMIR successfully; and risks related to the sufficiency of our cash resources, our anticipated capital requirements, our need or desire for additional financing, our ability to continue to meet the minimum bid price for continued listing on Nasdaq, our ability to obtain capital to fund our operations and expenses, and our ability to continue to operate as a going concern. Further information regarding these and other risks is included in DURECT's most recent Securities and Exchange Commission (SEC) filings, including its annual report on Form 10-K for the year ended December 31, 2023 and quarterly report on Form 10-Q for the quarter ended March 31, 2024, when filed, under the heading "Risk Factors." These reports are available on our website [www.durect.com](http://www.durect.com) under the "Investors" tab



and on the SEC's website at [www.sec.gov](http://www.sec.gov). All information provided in this press release and in the attachments is based on information available to DURECT as of the date hereof, and DURECT assumes no obligation to update this information as a result of future events or developments, except as required by law.

NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals, Ltd. in the U.S. and a trademark of DURECT Corporation outside of the U.S. SABER® is a trademark of DURECT Corporation. Other referenced trademarks belong to their respective owners. Larsucoferol is an investigational drug candidate under development and has not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.

SOURCE DURECT Corporation

Image not found or type unknown

